<DOC>
	<DOC>NCT00602407</DOC>
	<brief_summary>The objective of this study was the bioequivalence of a Roxane Laboratories' Cilostazol Tablets, 50 mg, to PLETALÂ® Tablets, 50 mg (OTSUKA Pharmaceuticals) under fasting conditions using a single-dose, randomized, 2-treatment, 2-period, crossover design.</brief_summary>
	<brief_title>Bioequivalency Study of 50 mg Cilostazol Tablets Under Fasting Conditions</brief_title>
	<detailed_description />
	<mesh_term>Intermittent Claudication</mesh_term>
	<mesh_term>Cilostazol</mesh_term>
	<criteria>No clinically significant abnormal findings on the physical examination, medical history, or clinical laboratory results during screening. Positive test for HIV, Hepatitis B, or Hepatitis C. Treatment with known enzyme altering drugs. History of allergic or adverse response to Cilostazol or any comparable or similar product.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2008</verification_date>
</DOC>